Summary. In this report we describe a patient who, after allogeneic bone marrow transplantation from her HLA-identical sister, developed polyendocrine failure in the form of Type 1 (insulin-dependent) diabetes mellitus and hypothyroidism. This was the result of the transfer of donor lymphoid cells which were activated by allogeneic bone marrow transplantation. The full chimerism of the recipient was demonstrated by restriction fragment length polymorphism analysis from nucleated blood cells and fibroblast DNA. During the 9-year follow-up, the donor developed hypothyroidism and signs of pre-Type 1 diabetes. This clinical observation resembles the adoptive transfer of diabetes observed in non-obesediabetic mice and BB rats and confirms the role of immune processes in the pathogenesis of this disease.
Type 1 (insulin-dependent) diabetesmellitus andhypothyroidism are recognised as organ specific autoimmune diseases occurring in genetically predisposed subjects after exposure to one or more environmental factors [1, 2] . The sequence of events which leads to the final destruction of pancreatic beta cells and thyrocytes remains poorly understood. In this report, we describe apatient who, after allogeneic bone marrow transplantation (BMT) for acute lymphoblastic leukaemia, developed an autoimmune reaction which led to polyendocrine failure. This was the result of transfer of donor lymphoid cells which were activated by the allogeneic BMT. The full chimerism of the lymphoid system oftherecipient was confirmed byDNApolymorphism analysis. In addition, the donor later developed autoimmune hypothyroidism and signs of pre-Type i diabetes. This is the first report of an adoptive transfer of Type 1 diabetes and hypothyroidism in a human subject. This model may enhance our understanding of the pathogenesis of these autoimmune diseases.
Case report (Fig. 1) The female patient was t3 years old when the diagnosis of acute lymphoblastic leukaemia was made in 1979. Blast cells were phenotypically CALLA (conunon acute lymphoblastic leukemia antigen) positive, and at the time of diagnosis, there was no visceral involvement or hyperleucocytosis. She went into complete remission after vincristine, prednisone and L-asparaginase treatment. She then received cranial irradiation (2400 rads) and intrathecal therapy with 6-mercaptopurine and methotrexate. Subsequently, she had five episodes of central nervous system relapse between June 1980 and December 1981 treated by both intra-thecal and intensive systemic chemotherapy. During this period, she was considered for an allogeneic BMT from her HLA-identical lymphoblastic leukaemia-cell negative sister. HLA phenotypes of the family were as follows: father: haplots~e a = Aw 32; B 37; DR-; haplotype b = A9W23; BW 51; DR4. Mother: haptotype c = A1; B8; DR 3; haplotype d = AW 33; B 27; DR-. DR-meant serologically undefined. The results of mixed lymphocyte cultu_re confirmed serological data and excluded a parental homozygosity of the HLA D region. The patient was identical to her sister with the phenotype a/c; her brother, diagnosed with Type 1 diabetes in 1975, had an HLA phenotype of a/r (r for recombination between B and DR: A 33, B 27, DR 3). Therefore, in comparison to both donor and recipient, he was haploidentical for HLA class I (a/d') but genoidentical for HLA class If (a/c"). Another brother who was in good health had phenotype b/d. The mother had been previously treated for Graves' disease. There was no other history of diabetes in the family.
The patient and her sister were ABO incompatible (types A and 0, respectively). Before grafting, the patient 3) and fibroblasts of the patient (lanes 2 and 4), digested either with Hinf I (lanes i and 2) or Hae IIi (lanes 3 and 4) and hybridized with minisatellite probe 15.1.11.4. Exposure time was 3 days quired insulin therapy and in view of positive anti-islet cell antibodies (ICA), she was started 38 months post-transplant on cyctosporin A (5 mg. kg-1. day-1 orally). L-thyroxine was also started for hypothyroidism. After 6 months of cyclosporin therapy no improvement of the diabetes was noted and immunosuppressive treatment was discontinued.
The patient is still alive 9 years after transplantation and receiving insulin, L-thyroxine and percutaneous oestrogen supplementation for secondary hypogonadism.
Restriction fragment length polymorphism analysis
was prepared with cyclophosphamide (60 mg/kg x 2) and total body irradiation (TBI) (1200 rads in 5 fractions). After removal of erythrocytes the donor received 2.1 x 105 marrow cells/kg body weight. Graft vs host disease (GVHD) was prevented by methotrexate (MTX) administration after grafting [3] . Full haematologic recovery had occurred by post-transplant day 32. Early transplant complications consisted of grade i acute GVHD, controlled by MTX therapy and cytomegalovirus infection with seroconversion by day 50. Five months post-BMT, the patient developed lichen planus of the skin, abnormal liver function tests, hypoproteinaemia and was considered for additional therapy with azathioprin only for chronic GVHD, while intra-thecal MTX was given every 2 months up to 2 years post-transplantation. One year post-transplantation, immunosuppressive therapy was discontinued. AB O evaluation confirmed a stable full donor chimerism. During the next 2 years, the patient was in good health with a normal fasting plasma glucose (below 5 retool/l). However, 3 years post-transplantation she developed polyuria, polydypsia, weight loss, after which Type i diabetes was diagnosed (plasma glucose 15.1 mmol/1). The patient reRestriction fragment length polymorphism was used to detect engraftment and chimerism in the recipient after BMT [4, 5] . As a blood sample from the donor was not available, the restriction enzyme patterns of DNAs prepared from the patient's blood and skin fibroblasts were compared. Minisatellite DNA probe 15.1.11.4 (a 600 base pair fragment, cloned in an M13 vector), obtained from Dr. A.J. Jeffreys (University of Leicester, Leicester, UK) was used, as it can detect many highly variable loci simultaneously [6, 7] . Single-stranded DNA was prepared and labelled in vitro as described previously [6] .
Ten gg aliquots of either blood or fibroblast DNA were digested with either Hinf I or Hae III using the conditions recommended by the manufacturer, submitted to agarose gel electrophoresis, transferred to nitrocellulose, and hybridized with i x 106 cpm/ml of denatured probe as described previously [8] . Blots were exposed to Kodak X A R 5 films at -80°C using intensifying screens. Figure 2 clearly demonstrates that different sets of labelled fragments were obtained in DNA isolated from nucleated blood cells and skin fibroblasts, indicating that the patient is a chimera. 
Serological methods and functional endocrine investigations
Serum samples from the patient and her sister were collected before and post-transplantation at regular intervals. Aliquots were kept frozen at -80°C and subsequently used for antibody (Ab) screening [9] . Anti-ICA were detected by conventional indirect immunofluorescence on frozen sections of human pancreas. Our laboratory has participated in the ICA Proficiency Programmes with the following result: sensitivity 81 and 100 %; specificity 95 and 100 %; consistency 90 and 95 %. Anti-glutamic acid decarboxylase (GAD) Ab were detected by an immunotrapping enzyme activity assay as described previously [10] . Results were expressed in arbitrary units as the percentage of the GAD activity trapped by a positive reference control. The positivity threshold was 0.11 units. Unfortunately GAD Ab levels could only be determined in the donor. Thyroid microsomal and thyroglobulin Ab were estimated by tanned erythrocyte haemagglutination using the microsome and thyroid test kits (Wellcome Diagnostics, Dartford, Kent, UK). Titers of 1:100 and 1:40 respectively, were considered positive.
Determination of acetylcholine receptor Ab was performed as described by San Marco et al. [9] . Several normal human sera were used as controls to exclude non-specific background labelling. The Ab titre was expressed as nmoles of 125I alpha bungarotoxin binding sites. Negative titres were defined as 0.5 nmol/1 and limit titres ranged from 0.5 to 1.0 nmolfl.
Several other anti-organ Ab were investigated as reported by San Marco et al. [9] . T3, T4 and thyroid stimulating hormone (TSH) levels were measured using conventional radioimmunoassay. Acute insulin response to i.v. glucose was evaluated by summation of plasma insulin values 2 and 5 min after the end of the i.v. glucose load (0.3 g/kg injected in 2 rain) as previously described [11] .
Autoantibody follow-up and clinical function of target organs in recipient
Serial frozen serum samples available prior to and following BMT were investigated with a series of anti-organ Ab. Results are summarized in Table 1 . Development of the various autoantibodies did not occur in parallel. Anti-cytoplasmic ICA became detectable only 15 months after grafting and were of the IgG type (IgG-ICA). No anti-ICA of the IgM type were detectable in any serum sample. IgG-ICA remained positive at a high titre during the 21 months preceding the clinical onset of the diabetes, and persisted despite cyclosporin A therapy.
High titre of anti-thyroid Ab appeared 7 months after the graft. The kinetics of anti-thyroglobulin and antimicrosomal Ab were identical, but the titre of anti-thyroglobulin Ab was always much higher. There was a progressive decline of the titres between 8 and 39 months. Subclinical hypothyroidism was diagnosed based on the low value of T3 (0.9 ng/ml) and T4 (0.9 ng/ml) and only a weak rise in TSH, which could be explained by previous cranial irradiation.
Anti-parietal gastric cells, anti-acetylcholine receptor and anti-smooth muscle Ab were consistently detected both during the follow-up, and prior to transplantation. No clinical signs of myasthenia gravis were observed, however, the Ab titres remained present but low. Ab directed against the inter-cellular substance of stratified epithelium and mitochondrial antigens were positive be- fore grafting, for 2months post-transplantation and thereafter disappeared. Anti-nuclear Ab were not detected.
Follow-up of the donor
The donor was unavailable for testing until 52 months after BIVIT (16 months after the onset of diabetes in the sister). At this time her fasting plasma glucose was normal (5.5 mol/1). ICA were undetectable. Anti GAD Ab were positive (0.355 units). Acute insulin response to glucose was in the normal range (Fig. 3) . Anti-thyroid Ab were positive (anti-thyroglobulin 1/20480 and anti-microsomal Ab 1/6400) and thyroid failure was characterized by a significant rise of TSH level (11 mU/1, normal range 0.25-3.5 mUff) with normal free T3 and free T4 levels. Other auto-antibodies were found to be negative (smooth muscle, gastric parietal, adrenal cells Ab, acetylcholine receptor Ab and mitochondria Ab). The donor was subsequently treated by L-thyroxine and submitted to a serial evaluation of markers of pre-Type i diabetes namely, ICA and GAD Ab measurement and evaluation of acute insulin response to i.v. glucose load. The follow-up of these markers is represented in Figure 2 . There was a progressive increase of ICA titre. Meanwhile a concomitant 
Discussion
This unique report of autoimmune polyendocrine failure with combined Type 1 diabetes and hypothyroidism after allogeneic BMT is st~ingly suggestive of an adoptive transfer of the disease by the transplantation of immunocompetent cells from the donor. The full haematopoietic chimerism of the recipient after BMT was documented by the erythropoietic chimerism for ABO markers and comparative analysis of fibroblast and lymphocyte DNA. Thus, it is likely that the production of anti-ICA and antithyroid Ab, and the destruction of the target cells in both pancreas and thyroid are due to lymphoid cells from the donor. In this context, the pathogenesis of the autoimmune disease may be due to either an active autoimmune phenomenon, as a part of the immune disorders associated with the GVHD [12] , or to a transfer of a subclinical autoimmune disease of the donor, activated to a clinical level by BMT [12, 13] . Most likely GVHD does not play a role in the pathogenesis of endocrine failure. Occurrence of autoantibodies has been described after allogeneic BMT, but anti-thyroid Ab and Anti-ICA are rare in comparison to other autoantibodies [9, 14, 15] . In animal studies, GVHD following BMT in semi-allogeneic F1 mice is associated with pathological evidence of severe lymphocytic infiltration of islets of Langerhans [16] . But in this model, glucose tolerance remained normal. Such observations have not been made in dogs or humans, where the rare pancreatic lesions which can be observed a£~er BMT, involve either exocrine pancreas or pancreatic and biliary ducts [17] . In this case report it is important to remember that anti-ICA were undetectable for the entire period where GVH reactions were observed in the patient. Humoral anti-pancreatic reaction became obvious when GVHD disappeared, after discontinuation of the post-graft immunosuppressive therapy. Thus, the hypothesis of an adoptive transfer of two organ specific autoimmune diseases is plausible. Similarly, other cases of transfer of diseases related to autoimmunity during BMT have been reported in the literature, including myasthenia gravis [18] [19] [20] [21] [22] and autoimmune thrombocytopoenic purpura [13, 23] . In one patient hypoglycaemia was induced by the transfer of anti-insulin receptor Ab [24] . Adoptive transfer of autoimmune thyroiditis has been previously reported by Wyatt et al. [25] and Aldouri et al. [26] . Adoptive transfer of hypothyroidism, seems likely in our patient as the donor was antibody positive and rapidly developed subclinical hypothyroidism. The situation is different for diabetes at the time of the BMT. One can speculate that anti-pancreatic clones of the donor were quiescent and activated by BMT in the recipient. In animal models, adoptive transfer of diabetes by splenocytes [27, 281 and bone marrow cells [29] has been reported. In BB rats previous in vitro activation of splenocytes is required [27] . In non-obese-diabetic mice the recipient has to be irradiated before reconstitution [28, 29] . Adoptive transfer of both diabetes and thyroiditis has been described in a modelin which the BB rat is donor and the athymic rat, recipient [30] . The follow-up of the donor in our study confirmed the presence of these resting autoreactive clones directed against islet beta cells. Anti-GAD Ab and a high titre of ICA became detectable several months later and a progressive loss of acute insulin response to i.v. glucose was observed. The combination of these pre-diabetes markers has been shown to have a good predictive value in family studies [10, 11, [30] [31] [32] . Therefore, the donor can be considered to be at a high risk for the development of Type 1 diabetes.
In the recipient the evolution could have been accelerated by BMT-induced activation of lymphocytes. Indeed BMT with or without GVHD complications, is a situation where post-graft lymphocyte activation has been demonstrated, and leads either to a T-lymphocyte population imbalance or to a polyclonal activation [33] [34] [35] . As seen in animal models, our patient exhibited both requisite conditions for diabetes transfer i.e. activation of donor cells, irradiation of recipient.
The HLA identity at the D locus with the pre-diabetic donor and the diabetic brother conferred to the patient a high susceptibility to Type i diabetes. According to Tarn et al. [36] her cumulative risk of becoming insulin-dependent by age 25 could be estimated at 16 %. But in addition, the HLA identity between donor and recipient probably also played an important role in allowing the general mechanisms of MHC-restricted T tymphocytoxicity. This observation represents a mirror image of the observations of Sibley et al. [37] . These authors showed that endocTine parts of the pancreatic graft from a non-diabetic twin or HLA identical sibling were destroyed by the diabetic twin with a re-onset of the causal autoimmune disorder. In our case report, the diabetes seems to occur after exposition of the target cells to immunocompetent cells which are MHC-compatible. In the case reports of Sibley et al. [37] , the time-lag between the transplantation and the recurrence of diabetes was shorter than in ours (2 to 3 months) and the recurrence of ICA was found in only two out of four subjects [37] .
In conclusion, one can conceive that the following sequence of events occurred after BMT in our patient: first-1~; activation in a susceptible genetic background of both weakly active (anti-thyroid) and quiescent (anti-ICA) clones of T lymphocytes; secondly, facilitation of the cytotoxic process by the MHC identity between the donor lymphocytes and the recipient target cells; thirdly, polyglandular failure by destruction of both endocrine cells. This clinical observation, very similar to adoptive transfer of autoimmune diabetes in animal models, confirms the contribution of the immune system to the pathogenesis of Type t diabetes.
